Daclatasvir based drugs: price, availability and description

Daclatasvir is a direct-acting antiviral agent that targets the NS5A protein required for hepatitis C virus (HCV) replication. It is never used as a monotherapy. Daclatasvir is indicated for use in combination with other agents, most commonly sofosbuvir, for the treatment of chronic hepatitis C genotypes 1, 2, 3, and 4. This combination has shown high cure rates.